Compugen Ltd. (CGEN)
NASDAQ: CGEN · Real-Time Price · USD
1.410
-0.010 (-0.70%)
At close: Sep 4, 2025, 4:00 PM
1.410
0.00 (0.00%)
After-hours: Sep 4, 2025, 4:04 PM EDT

Company Description

Compugen Ltd., a clinical-stage therapeutic discovery and development company, engages in the research, development, and commercialization of therapeutics and product candidates in Israel, the United States, and Europe.

The company’s pipeline consists of COM701, an immuno-oncology pipeline program with an anti-PVRIG antibody; COM902, a therapeutic anti-TIGIT antibody, are in Phase 1 clinical trials and have been evaluated for the treatment of solid tumors as a monotherapy and in combination of PVRIG/PD-1 and PVRIG/TIGIT, as well as PVRIG/PD-1/TIGIT blockade; Bapotulimab, a therapeutic antibody targeting ILDR2 that is evaluated in Phase I clinical trials in patients with naïve head and neck squamous cell carcinoma; and Rilvegostomig, a novel anti-TIGIT/PD-1 bispecific antibody, which is in Phase III clinical study in patients with advanced or metastatic non-small cell lung cancer.

Its preclinical therapeutic pipeline also includes early-stage immuno-oncology programs focused to address various mechanisms of immune resistance; and COM503, high affinity antibody, which blocks the interaction between IL-18 binding protein and IL-18.

The company has collaboration agreement with Bristol-Myers Squibb to evaluate the safety and tolerability of COM701 in combination with Bristol-Myers Squibb’s PD-1 immune checkpoint inhibitor Opdivo in patients with advanced solid tumors.

It has license agreement with AstraZeneca for the development of bi-specific and multi-specific immuno-oncology antibody products; and Gilead Sciences, Inc. for the research, development, manufacturing, and commercialization of COM503 and other products.

Compugen Ltd. was incorporated in 1993 and is headquartered in Holon, Israel.

Compugen Ltd.
Compugen logo
CountryIsrael
Founded1993
IPO DateAug 11, 2000
IndustryBiotechnology
SectorHealthcare
Employees74
CEOAnat Cohen-Dayag

Contact Details

Address:
Azrieli Center, Building D
Holon, 5885849
Israel
Phone972 3 765 8585
Websitecgen.com

Stock Details

Ticker SymbolCGEN
ExchangeNASDAQ
Fiscal YearJanuary - December
Reporting CurrencyUSD
CIK Code0001119774
CUSIP NumberM25722105
ISIN NumberIL0010852080
SIC Code2836

Key Executives

NamePosition
Dr. Anat Cohen-Dayag Ph.D.Chief Executive Officer, President and Director
Dr. Eran Ophir Ph.D.Chief Scientific Officer
Dr. Zurit Levine Ph.D.Senior Vice President of Strategic Collaborations
Dr. Pierre Ferre Ph.D.Senior Vice President of Preclinical Development and Corporate Operations
Michelle Mahler M.D.Chief Medical Officer
David Silberman CPAChief Financial Officer
Yvonne NaughtonHead of Investor Relations and Corporate Communications
Eran Ben DorGeneral Counsel and Corporate Secretary
Dorit AmitayVice President of Human Resources
Dr. Yaron Turpaz M.B.A., Ph.D.Senior Vice President and Senior Advisor of Data and Informatics Solutions

Latest SEC Filings

DateTypeTitle
Aug 6, 20256-KReport of foreign issuer
Aug 6, 20256-KReport of foreign issuer
Jul 21, 20256-KReport of foreign issuer
May 19, 20256-KReport of foreign issuer
May 13, 20256-KReport of foreign issuer
Mar 4, 202520-FAnnual and transition report of foreign private issuers
Mar 4, 20256-KReport of foreign issuer
Feb 14, 2025SCHEDULE 13G/AFiling
Jan 8, 20256-KReport of foreign issuer
Nov 27, 20246-KReport of foreign issuer